Overview: NGS Spastic Paraplegia NBIA Sequencing TestIntroduction: The NGS Spastic Paraplegia NBIA Sequencing Test sequences genes to diagnose spastic paraplegia or neurodegeneration with brain iron accumulation (NBIA), causing movement or neurological issues. Following 2023 AAN guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected hereditary spastic paraplegia (HSP) or NBIA.
Other Names: Spastic Paraplegia NGS Assay, HSP/NBIA Gene Panel.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: HSP and NBIA sequencing began in the 2000s with movement disorder research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose spastic paraplegia or NBIA, guides treatment, and evaluates patients with movement or neurological issues.
Test Parameters: 1. Spastic Paraplegia/NBIA Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of spasticity, movement issues, or NBIA symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document spasticity, movement issues, cognitive decline, or family history of HSP or NBIA. Include current medications, especially baclofen.
Consent: Written consent required, detailing the tests purpose, HSP/NBIA implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze HSP/NBIA genes (e.g., SPAST, PANK2). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for HSP or NBIA diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm HSP or NBIA, guiding supportive care or genetic counseling. Negative results may require brain MRI.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Brain MRI, EMG, or neurological exam to confirm HSP or NBIA diagnosis.
Test Limitations: Not all HSP or NBIA cases are genetic; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN HSP/NBIA Guidelines, 2023; Neurology, Hogarth P, 2022.
